WO1996032640A1 - Sensitive immunoassays utilizing antibody conjugates with replicable dna templates - Google Patents
Sensitive immunoassays utilizing antibody conjugates with replicable dna templates Download PDFInfo
- Publication number
- WO1996032640A1 WO1996032640A1 PCT/US1996/004494 US9604494W WO9632640A1 WO 1996032640 A1 WO1996032640 A1 WO 1996032640A1 US 9604494 W US9604494 W US 9604494W WO 9632640 A1 WO9632640 A1 WO 9632640A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rna
- variant
- antibody
- dna
- variant dna
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/682—Signal amplification
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/971—Capture of complex after antigen-antibody reaction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/973—Simultaneous determination of more than one analyte
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/824—Immunological separation techniques
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/828—Protein A
Definitions
- This invention is in the general field of immunochemistry. More specifically, the invention concerns sensitive immunoassays wherein antibodies conjugated to variant DNA templates are used with an appropriate RNA-dependent RNA polymerase, such as, QB replicase, in a novel signal amplification system that minimizes unwanted background signal.
- an appropriate RNA- dependent RNA polymerase such as, QB replicase
- Immunoassays for specific antigens are powerful tools for clinical diagnostics and for various molecular and cellular analyses.
- the instant invention is directed at enhancing the sensitivity of immunoassays by employing variant DNA as an amplifiable reporter molecule.
- the sensitivity of conventional immunoassays is in practice governed for a particular antibody-analyte interaction by the value of the equilibrium constant, which is normally referred to as the dissociation constant.
- the equilibrium or dissociation constant reflects the amount of antibody-analyte complex formed at given concentrations of reactants. Typical values for the dissociation constant are found in the range of 10 *7 M to 10 "12 M. For example, at an antibody concentration equal to the dissociation constant, approximately 50% of a trace analyte will be complexed with the antibody at equilibrium.
- Efforts to maximize sensitivity for immunoassays have included attaching labels, such as, enzymes, to antibodies such that the number of antibody-analyte complexes which can be detected is maximized.
- the ultimate goal in such an approach is to be able to detect a single analyte-antibody complex.
- An article by Chu et al., ucleic Acids Research. 3.4: 5591 (1986)] concerns the use of midivariant RNA as an amplifiable reporter to enhance the sensitivity of bioassays.
- Midivariant RNA serves as a template for its own replication which is catalyzed by QB replicase. [Miele et al., J. Mol. Biol..
- variant DNAs rather than midivariant RNA
- templates for RNA synthesis with appropriate RNA-dependent RNA polymerases, such as, QB replicase.
- variant DNA templates such as, nanovariant and midivariant DNA templates
- QB replicase RNA-dependent RNA polymerases
- variant DNA templates such as, nanovariant and midivariant DNA templates
- the immunoassay methodology of this invention employs variant DNA as an amplifiable label conjugated to an antibody or biologically active antibody fragment.
- the advantages for the use of the amplifiable DNA templates of this invention over their RNA counterparts as labels for antibodies are several.
- DNA is inherently more stable than RNA. Also, as indicated above, the relative inefficiency of the replication of the DNA templates can be used effectively to mask the potential signal generated from non-specific binding of the antibody conjugates, and thus, the assays of this invention should be more sensitive than assays employing corresponding RNA template conjugates.
- This invention in one aspect concerns immunoassay methods that use an antibody-variant DNA conjugate as a tracer antibody, wherein the variant DNA is a substrate for an RNA- dependent RNA polymerase.
- the use of said conjugate provides a novel signal amplification system for immunoassays.
- the antibody of the conjugate can be directed to either an analyte under assay or to an anti-analyte antibody used in an immunoassay.
- the variant DNA template, bound to the analyte is transcribed, and the RNA transcript is replicated by contact with an appropriate amount of an RNA-dependent RNA polymerase, whose substrate is the variant DNA, in the presence of ribonucleotides.
- the detection of RNA replication products produced in the assay indicates the presence of the analyte under assay.
- RNA replication products can also be quantitated, and the quantity of the replication products can be correlated with the quantity of the analyte assayed.
- the immunoassay methods of this invention can be used for detecting or, for detecting and quantitating analyte in a test sample.
- immunoassay methods of this invention can be used to detect, or to detect and quantitate, simultaneously two or more analytes in a test sample.
- Such methods comprise the use of two or more different antibody-variant DNA conjugates, wherein the variant DNA of different conjugates comprise different DNA sequences inserted therein, and wherein said inserted DNA sequences do not correspond to naturally occurring variant RNA sequences that are templates for RNA- dependent RNA polymerases.
- Those DNA sequences are preferably non-variant DNA.
- the inserted DNA sequences are preferably inserted at a position in the variant DNA other than within 10 bases from the 3' end, more preferably other than within 20 bases from the 3' end.
- the antibodies of different conjugates that is, antibodies conjugated to variant DNA containing different inserted DNA sequences
- antibodies that are conjugated to variant DNA containing the same inserted DNA sequence are specific for the same analyte.
- Nucleic acid probes, preferably RNA probes, that are complementary to the different variant RNA replication products are preferably used to detect, or, to detect and quantitate the RNA replication products of such immunoassay methods. Probes complementary to the same variant RNA replication products are similarly labeled, whereas probes complementary to different variant RNA replication products are differently labeled.
- Immunoassay reagents comprising the antibody-variant DNA conjugates of this invention are described below, as well as representative methods of preparing such conjugates.
- Exemplary immunoassay reagents include those wherein the variant DNA of said antibody-variant DNA conjugates is conjugated to the antibody of said conjugates through an avidin-biotin, preferably streptavidin-biotin, bridge, via
- exemplary regents can include variant DNA conjugated to avidin and/or Protein A.
- Different DNA sequences can be inserted in the variant DNA of the immunoassay reagents of this invention to provide reagents that generate individual amplifiable signals.
- Reagents containing such variant DNA with inserted DNA sequences can be used in methods of this invention to detect, or to detect and quantitate, simultaneously two or more analytes in a test sample.
- Immunoassay test kits comprise immunoassay regents of this invention and an apropriate RNA-dependent RNA polymerase, wherein the variant DNA of the reagents is a substrate for the polymerase.
- Such test kits can further comprise a solid phase to which an anti-analyte antibody or a receptor for the analyte under assay is attached.
- Other embodiments of such immunoassay test kits can comprise variant DNA conjugated to avidin, preferably streptavidin, and/or Protein A.
- RNA ribonucleic acid SMCC - succinimidyl 4-(N-maleimido-methyl) cyclohexane-1- carboxylate SPDP - N-succinimidyl-3-(2-pyridylthio)-propionate UTP - uridine triphosphate ⁇ M - micromolar ⁇ g - microgram
- aspects of this invention revolve around antibody- variant DNA conjugates that are immunoassay reagents.
- the conjugates are components of an immunoassay signal amplification system.
- the signal for an analyte molecule needs to be amplified, so that the signal is visualizable and thus detectable.
- the instant invention provides such a signal amplification system.
- the system can produce an amplified signal representative of the number of analyte molecules in a sample that is assayed by methods of this invention.
- the variant DNA of the conjugates when bound to an immunocomplex according to this invention is transcribed to RNA, and then the RNA transcripts are replicated, by contact with an appropriate RNA-dependent RNA polymerase in the presence of ribonucleotides, resulting in RNA replication products.
- RNA variant molecules can be produced.
- Those RNA replication products are rendered visualizable by an appropriate means, such as by labeling with a radionuclide, fluorescer, chemiluminescer, or enzyme or by staining with an intercalating dye, among other methods (as discussed infra) .
- Examples 1-3 demonstrate some representative methods of preparing the antibody-variant DNA conjugates of this invention.
- Example 4 demonstrates the ability of variant DNA conjugated to an antibody to serve as a template for an RNA-dependent RNA polymerase to synthesize RNA.
- nanovariant DNA conjugated to antibodies via the representative cross-linking reagent SPDP retains its capability to serve as a template for QB replicase catalyzed synthesis of nanovariant RNA.
- representative antibody-variant DNA conjugates of this invention may be used for immmunoassays of enhanced sensitivity.
- the overall antibody concentration is chosen so that the amount of conjugated antibody non-specifically bound and capable of amplification by a RNA-dependent RNA polymerase, such as, QB replicase, is approximately 1000 to 10,000 molecules.
- a RNA-dependent RNA polymerase such as, QB replicase
- the current replication sensitivity of a nanovariant DNA or midivariant DNA template in solution has been found by the inventors to be approximately 10,000 molecules. Since levels of DNA template below that level do not appear to yield detectable levels of RNA synthesis, no background signal may be expected from that level of non ⁇ specific binding. Thus 1000 to 10,000 molecules would be the theoretical limit of sensitivity for the immunoassays of this invention.
- a specific immunoassay can be optimized by methods known to those of skill in the art.
- binding to a second reagent such as, a second antibody attached to a solid phase would take place as in conventional immunoassay formats.
- a solid phase reagent facilitates the separation of the bound and unbound antibody-conjugate.
- a particularly prepared solid phase comprises a paramagnetic particle (PMP) [Ciba Corning Diagnostics Corp.; Medfield, Massachusetts (USA) ] .
- PMP paramagnetic particle
- capture antibody or receptor to the analyte under assay are attached to such PMPs, captured immunocomplexes can be separated from unbound antibody-variant DNA conjugates by applying a magnetic field. After separation and wash as in conventional immunoassays, the solid phase with the adsorbed antibody conjugate is incubated with an RNA-dependent RNA polymerase, such as, QB replicase to provide the amplified signal.
- an RNA-dependent RNA polymerase such as, QB replicase
- the variant RNA such as nanovariant RNA or midivariant RNA, synthesized in that amplification step is produced in sufficient quantities to render it detectable by a variety of methods, radioactive or non-radioactive, as are conventionally used.
- a preferred embodiment for practicing this invention would include, for example, incubating a test sample containing the analyte to be detected, or, to be detected and quantitated, with an antibody which binds specifically to the analyte and is conjugated with nanovariant or midivariant DNA for an appropriate amount of time. Another preferred embodiment would be to mix a small amount of such an antibody- variant DNA conjugate according to this invention with unconjugated antibody that is specific for the analyte to be determined.
- an exemplary immunoassay method of this invention for detecting, or, for detecting and quantitating an analyte in a test sample comprises the steps of:
- step (e) determining whether any variant RNA is replicated in step (d) and correlating the presence of RNA replication products with the presence of analyte; or detecting and quantitating variant RNA replicated in step (d) , and correlating the quantity of said RNA replication products with the quantity of analyte.
- Such a method can further comprise before step (c) or simultaneously with step (c) , contacting said test sample with a receptor for said analyte, or with an additional anti- analyte antibody which is directed to a different epitopic site on said analyte than to that which said second antibody, if present, is directed, or than to that which the corijugate antibody is directed, if said conjugate antibody is directed to an epitopic site on said analyte.
- analyte receptor or said anti-analyte antibody of such preferred embodiments can be immobilized upon a solid phase.
- exemplary of an analyte receptor are estrogen receptors, progesterone receptors, growth factor receptors, among many others.
- Another preferred embodiment is that wherein two or more analytes in a test sample are detected, or detected and quantitated simultaneously.
- Two or more different antibody- variant DNA conjugates are used in such an embodiment, wherein the variant DNA of different conjugates comprise different DNA sequences inserted therein, preferably at a position other than within 10 bases from the 3' end of the variant DNA, more preferably other than within 20 bases from the 3' end.
- Such inserted DNA sequences are sequences whose RNA counterparts do not naturally occur in variant RNA templates that are substrates for RNA-dependent RNA polymerases, such as, QB replicase. More preferably, such inserted sequences are non-vari nt DNA. [See. Martinelli et al., European Patent Application Publication No.
- the lengths of such inserted DNA sequences can be from about 10 nucleotides to about 120 nucleotides.
- the variant DNA is nanovariant or midivariant DNA, wherein the lengths of the inserted DNA sequences are preferably from about 10 nucleotides to about 50 nucleotides, more preferably from about 10 nucleotides to about 30 nucleotides.
- Midivariant DNA is particularly preferred according to this invention for inserting therein different DNA sequences.
- Inserted DNA sequences that have no RNA counterparts naturally occuring in midivariant RNA, which is a template for QB replicase, having lengths of from about 10 to about 120 bases, have been found to be transcribed and replicated successfully from midivariant DNA.
- Such sequences are preferably inserted in a midivariant DNA template at a position about in the middle of the midivariant DNA, or at a position about one quarter of the length of the midivariant DNA from the 5' end, that is, from about 55 to 70 bases from the 5' end.
- such inserted DNA sequences be inserted at a position in the positive strand of the midivariant DNA [MDV-1 (+) DNA] at about nucleotides 130 to 131, or at about nucleotides 61 to 64, more preferably at nucleotide 63.
- an embodiment of such assays for detecting, or for detecting and quantitating, simultaneously two or more different analytes in a test sample is that wherein the antibodies conjugated to variant DNA containing different inserted DNA sequences are specific for different analytes, whereas antibodies conjugated to variant DNA containing the same inserted DNA sequences are specific for the same analyte.
- antibodies conjugated to variant DNA containing different inserted DNA sequences are specific for different analytes
- antibodies conjugated to variant DNA containing the same inserted DNA sequences are specific for the same analyte.
- the different variant DNAs when bound respectively in immunocomplexes to different analytes, are transcribed, and the RNA transcripts are replicated, by contact with an appropriate RNA-dependent RNA polymerase.
- the different variant RNA replication products can be detected by hybridization to differently labeled nucleic acid probes, preferably RNA probes.
- the probes are complementary to the RNA counterparts of the DNA sequences inserted within the variant DNA of the conjugates.
- the probes hybridize under standard hybridization conditions, to the variant RNA replication products. Varying conditions of hybridization may be desired, depending on, for example, the specific immunoassay envisioned, the number of analytes to be detected or the selectivity of the probe towards the target RNA replication product sequence. Where a high degree of selectivity is desired, one may employ relatively stringent hybridization conditions, such as, relatively low salt and/or high temperature conditions. Under such conditions, relatively little mismatch between the probe and the target sequence is tolerated. Less stringent conditions may usually be desired when optimizing conditions for a specific immunoassay.
- a representative embodiment of a method according to this invention for detecting, or for detecting and quantitating, two or more analytes simultaneously in a test sample comprises performing the exemplary immunoassay, outlined above in relation to a single analyte, simultaneously with two or more different antibody-variant DNA conjugates, wherein the antibody-variant DNA conjugates differ in that the variant DNA of the different conjugates comprise different DNA sequences inserted therein.
- the DNA sequences inserted in the variant DNA are the same when conjugated to antibodies having similar binding specificities, whereas the inserted DNA sequences are different in variant DNAs conjugated to antibodies having different binding specificities.
- an exemplary immunoassay method of this invention for detecting, or detecting and quantitating, two or more analytes simultaneously in a test sample comprises the steps of:
- variant DNA of different conjugates comprises different DNA sequences inserted therein; wherein the antibodies conjugated to variant DNA containing different inserted DNA sequences are specific for different analytes, whereas the antibodies conjugated to variant DNA containing the same inserted DNA sequence are specific for the same analyte; and wherein the variant DNA of said conjugates is a substrate for an RNA-dependent RNA polymerase;
- step (e) determining whether any variant RNA is replicated in step (d) , and, if so, determining from which variant DNA template or templates, said variant RNA was transcribed, and correlating the presence of RNA replication products generated from a certain variant DNA template with the presence of the corresponding analyte, that is, the analyte, for which the antibody to which that certain variant DNA is conjugated is specific; or determining from which variant DNA template or templates, said variant RNA replicated in step (d) was transcribed, quantitating each of the different variant RNA replication products, and correlating the quantity of each of the RNA replication products with the quantity of each corresponding analyte.
- the different variant RNAs replicated from the different variant DNA templates are preferably detected in step (e) by employing two or more differently labeled nucleic acid probes that are complementary to the different variant RNAs that are replicated, and wherein the probes that are complementary to one type of replicated variant RNA are similarly labeled.
- the differently labeled nucleic acid probes are RNA probes, and are complementary respectively to the different DNA sequences inserted in said different variant DNAs.
- An antibody-variant DNA conjugate of this invention can be a universal immunoassay reagent or can be directed against a specific analyte.
- Embodiments wherein the antibody- variant DNA conjugate is a universal type reagent may be preferred for certain immunoassays.
- an exemplary universal reagent would be that wherein the antibody of the conjugate is directed against antibodies that originated by immunizing a mammal of a different genus, than that from which the conjugate antibody originated.
- the antibody of the conjugate could be a goat anti-mouse antibody, and thus be useful as a component of a signal amplification system for any immunoassay employing mouse antibodies.
- antibodies are antibodies functionally equivalent to such antibodies, as represented by a goat anti- mouse antibody, as, for example, those that are genetically engineered or otherwise prepared, and biologically active antibody fragments.
- the antibody-variant DNA conjugate can be considered to be a universal type of immunoassay reagent is that wherein the variant DNA is linked to avidin, and biotinylated anti-analyte antibodies are used.
- the universal immunoassay reagent is actually the variant DNA linked to avidin, preferably the variant DNA linked to streptavidin.
- the variant DNA-antibody conjugate in that embodiment is prepared during the immunoassay procedure.
- RNA-dependent RNA polymerases are herein sometimes referred to as "replicases.” It is generally considered known in the art is that such replicases are enzymes that replicate, that is, reproduce, RNA transcripts and their complements so as to multiply copies thereof. When a replicase is present during the process of transcription, it can be forseen that the multiple transcripts that are produced during transcription can themselves undergo replication so as to increase exponentially the amount of RNA transcript product.
- a replicase functions to replicate exponentially an RNA transcript as long as the replicase is in molar excess over the RNA strands produced.
- the variant DNA of the conjugate of this invention thus serves as a template for the synthesis of a complementary RNA strand. After N rounds of replication, there will be 2 N strands produced for each initial template strand.
- RNA replicases have been isolated from Escherichia coli RNA phages [Lewin, B. in Gene Expression. 3: 790-824 (John Wiley & Sons; 1977)]; from plant RNA viruses [Miller et al., J. Mol. Biol.. 187: 537 (1986)], and as a secondary catalytic activity present in T7 RNA polymerase [Konarska and Sharp, Cell. 57: 427 (1989)].
- QB replicase is the best characterized of the RNA replicases.
- QB replicase is a particularly preferred replicase for use in the immunoassay methods of this invention. [See, Miele et al., "Autocatalytic Replication of a Recombinant RNA," J. Mol.
- QB replicase can be isolated from bacteriophage QB-infected Escherichia coli. by the procedure of Eoyang and August in Procedures in Nucleic Acid Research. 2: 829-839, [eds. Cantoni and Davies (Harper and Row, N.Y. ; 1971) ].
- the QB virus is an RNA phage of approximately 4400 ribonucleotides. [See. Blumenthal in The Enzyme. Vol. XV. Part B, p. 267, ed. P.D. Boyer (Academic Press, N.Y.; 1982).] Although QB replicase replicates only QB RNA and not other viral RNA sequences, shorter, RNA sequences can also serve as templates for replication. Those shorter templates include "nanovariant" RNA which is 90 ribonucleotides in length and "midivariant" RNA which is 220 ribonucleotides in length.
- RNA-dependent RNA-polymerases that can be used as part of the signal amplification system of the immunoassays of this invention include the RNA phage replicases SP, MS2 and GA. [See. Mills et al., J. Mol. Biol..
- Another replicase that may be useful in the methods of this invention is the Brome Mosaic Virus replicase. [March et al., Positive Strand RNA Viruses (Alan R. Liss; N.Y.; 1987).] Other replicases and their associated substrates, can be found in Miyake et al., PNAS (USA), 68: 2022 (1971).
- Variant DNAs correspond to variant RNAs which are substrates for replicases.
- midivariant DNA corresponds to midivariant RNA.
- Preferred variant DNAs according to this invention are nanovariant, midivariant, microvariant and minivariant DNAs; more preferred are nanovariant and midivariant DNAs, most preferably those that are substrates for QB replicase; and further preferred are nanovariant DNAs that are substrates for QB replicase.
- antibodies is defined herein to include not only whole antibodies but also biologically active fragments of antibodies, preferably fragments containing the antigen binding regions. Such antibodies may be prepared by conventional methodology and/or by genetic engineering. Antibody fragments may be genetically engineered, preferably from the variable regions of the light and/or heavy chains (V H and V L ) , including the hypervariable regions, and still more preferably from both the V H and V L regions.
- V H and V L variable regions of the light and/or heavy chains
- antibodies as used herein comprehends polyclonal and monoclonal antibodies and biologically active fragments thereof including among other possibilities “univalent” antibodies [Glennie et al., Nature, 295: 712 (1982)]; Fab proteins including Fab' and F(ab') 2 fragments whether covalently or non-covalently aggregated; light or heavy chains alone, preferably variable heavy and light chain regions (V H and V L regions) , and more preferably including the hypervariable regions [otherwise known as the complementarity determining regions (CDRs) of said V H and V L regions] ; F c proteins; "hybrid” antibodies capable of binding more than one antigen; constant-variable region chimeras; "composite” immunoglobulins with heavy and light chains of different origins; "altered” antibodies with improved specificity and other characteristics as prepared by standard recombinant techniques and also by oligonucleotide-directed mutagenesis techniques [Dalbadie-M
- Fab fragments are particularly preferred fragments in accordance with this invention to avoid non ⁇ specific binding.
- Antibodies for use in the instant invention can be genetically engineered.
- Examples 1 and 2 Two general approaches to prepare antibody-variant DNA conjugates of this invention are shown in Examples 1 and 2 below.
- a derivative of nanovariant DNA such as PM444 (SEQ. ID. NO.: 1) [Promega; Madison, WI (USA)]
- a primary amine was conjugated to mildly reduced antibodies via a heterobifunctional group, such as SPDP.
- an amino- derivatized nanovariant DNA can be coupled to an antibody's amine groups by using a heterobifunctional group, such as SPDP.
- RNA replicases such as, QB replicase, initiate product strand synthesis at the 3' end.
- Further preferred methods for preparing such an amino- derivatized variant DNA comprise the use of a DNA synthesizer.
- Other coupling agents preferably heterobifunctional linking agents, known to those in the art, include m-maleimidobenzoyl N-hydroxysuccinimide ester [Kitagawa, T. in Enzvme Immunoassay (eds.
- a variant DNA preferably nanovariant or midivariant DNA
- avidin preferably streptavidin
- biotin could be attached to the 5' terminus of midivariant or nanovariant DNA via a disulfide linker, and the biotinylated DNA could be combined with avidin to form a DNA-biotin-avidin adduct, which then could be conjugated to biotinylated antibodies.
- Other methods of attaching avidin to variant DNA are known to those in the art such as methods employing Protein A. [See, for example, Sano et al., Science 258: 120 (2 Oct. 1992).]
- RNA replication products produced by the immunoassay methods of this invention there are many conventional means to detect the RNA replication products produced by the immunoassay methods of this invention. They include the incorporation of radioactive labels, e.g. Harper et al., Chromosoma. 83: 431-439 (1984); direct attachment of fluorochromes or enzymes, e.g. Smith et al., Nuc. Acids Res.. 13: 2399-2412 (1985), and Connolly et al., Nuc. Acids Res.. 13: 4485-4502 (1985); and various chemical modifications of nucleic acids that render them detectable immunochemically or by other affinity reactions, e.g.
- Exemplary detection means include the use of labels, such as, radionuclides, enzymes, coenzymes, fluorescers, chemiluminescers, chromogens, enzyme substrates, enzyme co-factors, enzyme inhibitors, free radicals, particles, dyes and the like.
- exemplary labeling means include those wherein the RNA replication products are biotinylated, modified with N-acetoxy-N-2-acetylaminofluorene, modified with fluorescein isothiocyanate, sulfonated, digoxigeninated, modified to contain T-T dimers or stained with an intercalating dye.
- the RNA replication products are detected by chemiluminescent methodology. See U.S. Patent No. 4,745,181. The use of acridinium ester as a chemiluminescer is particularly preferred.
- Example 4 details a representative detection means wherein radioactively labeled ribonucleotides ( 3 P-CTPs) are incorporated in the RNA replication products.
- radioactively labeled ribonucleotides 3 P-CTPs
- fluorochromes, enzymes or other labels may be incorporated in the replication products.
- Another exemplary method for incorporating fluorescent nucleotides in replicated RNA is shown in Cosstick et al., Nuc. Acids Res.. 12: 1791 (1984).
- electrophoretic means such as, the use of polyacrylamide gel electrophoresis, could be used to detect and/or quantitate the RNA replication products. [See, for example, Sano et al., Science. 258: 120 (2 October 1992).]
- Another detection methodology incorporates the use of optical devices to propagate radiation by "total internal reflection” to generate an evanescent wave at the interface of the device and a test medium having a lower index of refraction. See Harrick, N.J. , Internal Reflection Spectroscopy (Harrick Scientific Corp; N.Y; 3rd printing 1987); and U.S. Patent No. 4,880,752.
- the signal generated from the replication products indicates the presence of the analyte under assay. That signal may also be used to quantitate the amount of the analyte present in the assay by methods known to those of skill in the art.
- the amount of time it takes to synthesize a particular, though arbitrary, mass of amplified RNA from the variant DNA templates is directly related to the logarithm of the number of DNA molecules present at the start of the assay (time zero) .
- the amount of amplified RNA can be measured, for example, by the florescence of an intercalating dye, such as, ethidium bromide.
- an intercalating dye such as, ethidium bromide.
- the signal amplification system of this invention can be used in a variety of immunoassay formats, such as, sandwich assays, competition assays, bridge immunoassays, among other formats well known to those of skill in the art.
- immunoassay formats such as, sandwich assays, competition assays, bridge immunoassays, among other formats well known to those of skill in the art.
- Example l The nanovariant DNA used in the examples described herein is PM444 [Promega].
- PM444 has the following nucleotide sequence:
- a primary amine group was introduced into PM444 at its 3' terminus using terminal transferase with either aminohexyl-ATP or a combination of aminohexyl-ATP and dATP.
- the product of this reaction was labeled at its 5' terminus with 32 P with polynucleotide kinase and gamma 32 P-ATP.
- RNA-DNA hybrid 100 nM was reduced with dithiothreitol (DTT) (20 M) at room temperature for 30 min in 50 mM NaP0 4 , 150 mM NaCL, 1 mM EDTA (PBSE) .
- DTT dithiothreitol
- the reduced antibody was desalted on Sephadex G-25 in PBSE.
- the SPDP-derivatized oligomer was incubated with the reduced antibody at room temperature overnight.
- the antibody-DNA conjugate formed in this reaction was purified by affinity chromatography on Affigel Protein A [Biorad; Hercules, CA (USA)].
- 32 P labeled oligomer which bound to the column did so by virtue of its conjugation to the antibody.
- Bound material was eluted from the column with 0.1 M sodium citrate, pH 3 and neutralized by the addition of 1 M Tris, pH 9. The fractions containing 32 P were identified by liquid scintillation counting.
- Example 2 Anti-RNA-DNA hybrid monoclonal antibody (15 ⁇ M) and SPDP (100 ⁇ M) were reacted at room temperature for 1 hr.
- the derivatized antibody was desalted on Sephadex G25.
- the amino-oligomer (10 nM) that is, the a ino derivatized PM444 as prepared in Example 1, was also incubated with SPDP (100 ⁇ M) at room temperature for 1 hr. To that solution, DTT was added to give a final concentration of 0.1 M, and reduction proceeded for 10 minutes.
- the thiol- derivatized oligomer resulting from the reaction was desalted on Sephadex G-25.
- the oligomer was then incubated with the SPDP- derivatized antibody at room temperature overnight.
- the antibody-oligomer conjugate formed was purified by affinity chromatography on Affigel Protein A as described above in Example 1.
- Example 3 A version of PM444 containing an amine group at its 5' terminus was prepared, and labeled at its 3' terminus with 32 P-dideoxy-ATP with terminal transferase. That version of PM444, called PM653 [Promega] , was also coupled to antibody via SPDP by using each of the methods described above in Examples 1 and 2.
- Example 4 The ability of antibody-conjugated variant DNA to serve as a template for QB replicase catalyzed synthesis of variant RNA was examined.
- exemplary of such antibody- conjugated variant DNA is the antibody-conjugated nanovariant DNA, that is, the antibody-PM444 conjugates, prepared as described in Examples 1 and 2. The antibody-PM444 conjugates were incubated with
- RNA synthesis was due to contamination by nanovariant RNA
- either no antibody conjugate was added to the replicase reactions, or the antibody conjugates were digested with deoxyribonuclease [DNAse; Promega] at 37°C for 1 hr prior to addition to the replicase reaction.
- DNAse deoxyribonuclease
- Antibody-PM4 4 0.62 Antibody-PM444 + DNAse 0.11 PM444 1.65 PM444 + DNAse 0.07
- MOLECULE TYPE DNA (nanovariant)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU58503/96A AU5850396A (en) | 1995-04-04 | 1996-04-01 | Sensitive immunoassays utilizing antibody conjugates with replicable DNA templates |
BR9604965A BR9604965A (en) | 1995-04-04 | 1996-04-01 | Sensitive immunological tests using antibody conjugates with replicable DNA matrices |
MX9707635A MX9707635A (en) | 1995-04-04 | 1996-04-01 | Sensitive immunoassays utilizing antibody conjugates with replicable dna templates. |
JP8531046A JPH11503828A (en) | 1995-04-04 | 1996-04-01 | Highly sensitive immunoassay using a conjugate of a replicable DNA template and an antibody |
AT96920100T ATE206520T1 (en) | 1995-04-04 | 1996-04-01 | SENSITIVE IMMUNE TEST USING ANTIBODY CONJUGATES WITH REPLICAABLE DNA MATRICES |
EP96920100A EP0819249B1 (en) | 1995-04-04 | 1996-04-01 | Sensitive immunoassays utilizing antibody conjugates with replicable dna templates |
PL96322650A PL322650A1 (en) | 1995-04-04 | 1996-04-01 | Sensitive tests using conjugatesof antibodies with repeatable dna matrices |
DE69615673T DE69615673D1 (en) | 1995-04-04 | 1996-04-01 | SENSITIVE IMMUNITY TEST USING ANTIBODY CONJUGATES WITH REPLICABLE DNA MATRICES |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/416,571 | 1995-04-04 | ||
US08/416,571 US6083689A (en) | 1990-10-16 | 1995-04-04 | Sensitive immunoassays utilizing antibody conjugates with replicable DNA templates |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996032640A1 true WO1996032640A1 (en) | 1996-10-17 |
Family
ID=23650484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/004494 WO1996032640A1 (en) | 1995-04-04 | 1996-04-01 | Sensitive immunoassays utilizing antibody conjugates with replicable dna templates |
Country Status (12)
Country | Link |
---|---|
US (1) | US6083689A (en) |
EP (1) | EP0819249B1 (en) |
JP (1) | JPH11503828A (en) |
KR (1) | KR19980703574A (en) |
AT (1) | ATE206520T1 (en) |
AU (1) | AU5850396A (en) |
BR (1) | BR9604965A (en) |
CA (1) | CA2216466A1 (en) |
DE (1) | DE69615673D1 (en) |
MX (1) | MX9707635A (en) |
PL (1) | PL322650A1 (en) |
WO (1) | WO1996032640A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0813064A1 (en) * | 1996-06-10 | 1997-12-17 | Bayer Corporation | Method for amplification of the response signal in a sandwich immunoassay |
DE19959857C1 (en) * | 1999-12-10 | 2001-06-28 | Aventis Res & Tech Gmbh & Co | Test system for the detection of analytes and a method for the production and use |
WO2002016635A2 (en) * | 2000-08-25 | 2002-02-28 | Friz Biochem Gmbh | Method for marking chemical substances |
GB2375822A (en) * | 2000-12-05 | 2002-11-27 | Norchip As | Immunoassay using nucleic acid amplification and real-time measurement |
WO2003048388A2 (en) * | 2001-12-07 | 2003-06-12 | The University Of Liverpool | Immuno polymerase chain reaction assay |
WO2005003394A3 (en) * | 2003-06-27 | 2005-07-28 | Nanosphere Inc | Bio-barcode based detection of target analytes |
WO2006078289A3 (en) * | 2004-05-12 | 2007-02-08 | Nanosphere Inc | Bio-barcode based detection of target analytes |
WO2022231730A3 (en) * | 2021-03-22 | 2023-01-26 | Northwestern University | Synthetic strategy to polymerize protein into molecularly defined polymers |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020031788A1 (en) * | 2000-02-18 | 2002-03-14 | Rosenberg E. William | Characterization of microbial deposition and immune response at the basement membrane and methods relating thereto |
US7846733B2 (en) | 2000-06-26 | 2010-12-07 | Nugen Technologies, Inc. | Methods and compositions for transcription-based nucleic acid amplification |
ATE475720T1 (en) * | 2000-12-13 | 2010-08-15 | Nugen Technologies Inc | METHODS AND COMPOSITIONS FOR GENERATING MULTIPLE COPIES OF NUCLEIC ACID SEQUENCES AND METHODS FOR DETECTING THE SAME |
BR0205268A (en) * | 2001-03-09 | 2004-11-30 | Nugen Technologies Inc | Processes and compositions for mRNA sequence mplification |
US20020168667A1 (en) * | 2001-03-23 | 2002-11-14 | Fuji Photo Film Co., Ltd. | Antigen detecting agent and antigen detecting kit, antigen detecting apparatus and antigen detecting method using the same |
US20030003476A1 (en) * | 2001-03-23 | 2003-01-02 | Fuji Photo Film Co., Ltd. | Waste water inspecting agent and waste water inspecting apparatus using the same |
US20020168756A1 (en) | 2001-03-23 | 2002-11-14 | Fuji Photo Film Co., Ltd. | Particle size variable reactor |
US7018795B2 (en) | 2001-03-23 | 2006-03-28 | Fuji Photo Film Co., Ltd. | Hybridization probe and target nucleic acid detecting kit, target nucleic acid detecting apparatus and target nucleic acid detecting method using the same |
US7077982B2 (en) * | 2001-03-23 | 2006-07-18 | Fuji Photo Film Co., Ltd. | Molecular electric wire, molecular electric wire circuit using the same and process for producing the molecular electric wire circuit |
US20020168291A1 (en) * | 2001-03-23 | 2002-11-14 | Fuji Photo Film Co., Ltd. | Agent for health inspection and health inspection apparatus using the same |
JP3691428B2 (en) * | 2001-11-12 | 2005-09-07 | 三菱電機株式会社 | Aircraft display device |
US20030175828A1 (en) * | 2002-03-15 | 2003-09-18 | Lazar James G. | Signal amplification by Hybrid Capture |
US20030179381A1 (en) * | 2002-03-18 | 2003-09-25 | Fuji Photo Film Co., Ltd. | Sensor, color sensor and apparatus for inspection using the same |
US20040053399A1 (en) * | 2002-07-17 | 2004-03-18 | Rudolf Gilmanshin | Methods and compositions for analyzing polymers using chimeric tags |
JP4294946B2 (en) * | 2002-12-13 | 2009-07-15 | 富士フイルム株式会社 | Target detection apparatus, target detection method, and target detection substrate |
US7076127B2 (en) * | 2003-01-14 | 2006-07-11 | Fuji Photo Film Co., Ltd. | Optical switch and safety apparatus using the same |
WO2004092418A2 (en) | 2003-04-14 | 2004-10-28 | Nugen Technologies, Inc. | Global amplification using a randomly primed composite primer |
EP1615948B1 (en) | 2003-04-18 | 2015-04-01 | Becton Dickinson and Company | Immuno-amplification |
US20060199194A1 (en) * | 2003-11-10 | 2006-09-07 | Q-Rna, Inc. | Methods of detection using immuno-Q-Amp technology |
US20050214805A1 (en) * | 2003-11-10 | 2005-09-29 | Q-Rna, Inc. | Methods of detection employing immuno-Q-Amp technology |
US7977048B2 (en) * | 2004-01-13 | 2011-07-12 | Pathogenetix, Inc. | Detection and quantification of analytes in solution using polymers |
WO2005089524A2 (en) * | 2004-03-19 | 2005-09-29 | U.S. Genomics, Inc. | Compositions and methods for detection of single molecules |
US20060204999A1 (en) * | 2005-03-14 | 2006-09-14 | Stephen Macevicz | Detecting molecular complexes |
WO2007030759A2 (en) | 2005-09-07 | 2007-03-15 | Nugen Technologies, Inc. | Improved nucleic acid amplification procedure |
WO2007056250A2 (en) * | 2005-11-04 | 2007-05-18 | U.S. Genomics, Inc. | Heterogeneous assay of analytes in solution using polymers |
US20100294665A1 (en) * | 2007-07-12 | 2010-11-25 | Richard Allen | Method and system for transferring and/or concentrating a sample |
US20090203531A1 (en) * | 2008-02-12 | 2009-08-13 | Nurith Kurn | Method for Archiving and Clonal Expansion |
GB2470672B (en) | 2008-03-21 | 2012-09-12 | Nugen Technologies Inc | Methods of RNA amplification in the presence of DNA |
KR101029343B1 (en) * | 2009-07-30 | 2011-04-13 | 한국과학기술연구원 | Immunoassay-based Antigen Detecting Kit and Method |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4957858A (en) * | 1986-04-16 | 1990-09-18 | The Salk Instute For Biological Studies | Replicative RNA reporter systems |
EP0481704A1 (en) * | 1990-10-16 | 1992-04-22 | Ciba Corning Diagnostics Corp. | Amplification of midivariant DNA templates |
US5395752A (en) * | 1993-03-19 | 1995-03-07 | Ciba Corning Diagnostics Corp. | Long emission wavelength chemiluminescent compounds and their use in test assays |
US5451505A (en) * | 1989-05-22 | 1995-09-19 | Hoffmann-La Roche Inc. | Methods for tagging and tracing materials with nucleic acids |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4786600A (en) * | 1984-05-25 | 1988-11-22 | The Trustees Of Columbia University In The City Of New York | Autocatalytic replication of recombinant RNA |
US4883750A (en) * | 1984-12-13 | 1989-11-28 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
US5242794A (en) * | 1984-12-13 | 1993-09-07 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
EP0446305B1 (en) * | 1988-12-05 | 1996-05-08 | The Salk Institute For Biological Studies | Systems for amplification/detection of target nucleic acids |
US5112734A (en) * | 1989-05-26 | 1992-05-12 | Gene-Trak Systems | Target-dependent synthesis of an artificial gene for the synthesis of a replicatable rna |
-
1995
- 1995-04-04 US US08/416,571 patent/US6083689A/en not_active Expired - Fee Related
-
1996
- 1996-04-01 EP EP96920100A patent/EP0819249B1/en not_active Expired - Lifetime
- 1996-04-01 KR KR1019970706978A patent/KR19980703574A/en not_active Application Discontinuation
- 1996-04-01 PL PL96322650A patent/PL322650A1/en unknown
- 1996-04-01 AU AU58503/96A patent/AU5850396A/en not_active Abandoned
- 1996-04-01 JP JP8531046A patent/JPH11503828A/en active Pending
- 1996-04-01 AT AT96920100T patent/ATE206520T1/en not_active IP Right Cessation
- 1996-04-01 MX MX9707635A patent/MX9707635A/en unknown
- 1996-04-01 WO PCT/US1996/004494 patent/WO1996032640A1/en not_active Application Discontinuation
- 1996-04-01 BR BR9604965A patent/BR9604965A/en not_active Application Discontinuation
- 1996-04-01 DE DE69615673T patent/DE69615673D1/en not_active Expired - Lifetime
- 1996-04-01 CA CA002216466A patent/CA2216466A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4957858A (en) * | 1986-04-16 | 1990-09-18 | The Salk Instute For Biological Studies | Replicative RNA reporter systems |
US5451505A (en) * | 1989-05-22 | 1995-09-19 | Hoffmann-La Roche Inc. | Methods for tagging and tracing materials with nucleic acids |
EP0481704A1 (en) * | 1990-10-16 | 1992-04-22 | Ciba Corning Diagnostics Corp. | Amplification of midivariant DNA templates |
US5407798A (en) * | 1990-10-16 | 1995-04-18 | Ciba Corning Diagnostics Corp. | Amplification of midivariant DNA templates |
US5395752A (en) * | 1993-03-19 | 1995-03-07 | Ciba Corning Diagnostics Corp. | Long emission wavelength chemiluminescent compounds and their use in test assays |
Non-Patent Citations (3)
Title |
---|
CLINICAL CHEMISTRY, 1991, Vol. 37, No. 9, CAHILL et al., "Polymerase Chain Reaction and Qbeta Replicase Amplification", pages 1482-1485. * |
SCIENCE, 02 October 1992, Vol. 258, SANO et al., "Immuno-PCR: Very Sensitive Antigen Detection by Means of Specific Antibody-DNA Conjugates", pages 120-122. * |
TIBTECH, February 1991, Vol. 9, LIZARDI et al., "Exponential Amplification of Nucleic Acids: New Diagnostics Using DNA Polymerases and RNA Replicases", pages 53-58. * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0813064A1 (en) * | 1996-06-10 | 1997-12-17 | Bayer Corporation | Method for amplification of the response signal in a sandwich immunoassay |
DE19959857C1 (en) * | 1999-12-10 | 2001-06-28 | Aventis Res & Tech Gmbh & Co | Test system for the detection of analytes and a method for the production and use |
WO2002016635A2 (en) * | 2000-08-25 | 2002-02-28 | Friz Biochem Gmbh | Method for marking chemical substances |
DE10041766A1 (en) * | 2000-08-25 | 2002-03-14 | Friz Biochem Gmbh | Process for marking chemical substances |
WO2002016635A3 (en) * | 2000-08-25 | 2003-06-05 | Friz Biochem Gmbh | Method for marking chemical substances |
GB2375822B (en) * | 2000-12-05 | 2005-04-06 | Norchip As | Real time ligand detection comprising isothermal amplification |
GB2375822A (en) * | 2000-12-05 | 2002-11-27 | Norchip As | Immunoassay using nucleic acid amplification and real-time measurement |
US7910294B2 (en) | 2000-12-05 | 2011-03-22 | Norchip A/S | Ligand detection method |
WO2003048388A2 (en) * | 2001-12-07 | 2003-06-12 | The University Of Liverpool | Immuno polymerase chain reaction assay |
WO2003048388A3 (en) * | 2001-12-07 | 2003-09-25 | Univ Liverpool | Immuno polymerase chain reaction assay |
WO2005003394A3 (en) * | 2003-06-27 | 2005-07-28 | Nanosphere Inc | Bio-barcode based detection of target analytes |
WO2006078289A3 (en) * | 2004-05-12 | 2007-02-08 | Nanosphere Inc | Bio-barcode based detection of target analytes |
AU2005325273B2 (en) * | 2004-05-12 | 2009-07-02 | Nanosphere, Inc. | Bio-barcode based detection of target analytes |
WO2022231730A3 (en) * | 2021-03-22 | 2023-01-26 | Northwestern University | Synthetic strategy to polymerize protein into molecularly defined polymers |
Also Published As
Publication number | Publication date |
---|---|
JPH11503828A (en) | 1999-03-30 |
US6083689A (en) | 2000-07-04 |
EP0819249A4 (en) | 1999-04-14 |
AU5850396A (en) | 1996-10-30 |
BR9604965A (en) | 1998-07-14 |
EP0819249A1 (en) | 1998-01-21 |
PL322650A1 (en) | 1998-02-16 |
DE69615673D1 (en) | 2001-11-08 |
EP0819249B1 (en) | 2001-10-04 |
ATE206520T1 (en) | 2001-10-15 |
MX9707635A (en) | 1997-12-31 |
KR19980703574A (en) | 1998-11-05 |
CA2216466A1 (en) | 1996-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0819249B1 (en) | Sensitive immunoassays utilizing antibody conjugates with replicable dna templates | |
US5656731A (en) | Nucleic acid-amplified immunoassay probes | |
US4748111A (en) | Nucleic acid-protein conjugate used in immunoassay | |
EP0611828B1 (en) | Composition for use in an assay method utilizing polynucleotide sequences | |
EP0481704B1 (en) | Amplification of midivariant DNA templates | |
EP1255861B1 (en) | Methods and kits for proximity probing | |
US4824775A (en) | Cells labeled with multiple Fluorophores bound to a nucleic acid carrier | |
AU659798B2 (en) | Protein-nucleic acid probes and immunoassays using same | |
EP0163220B1 (en) | Nucleic acid hybridization assay employing detectable anti-hybrid antibodies | |
US5902724A (en) | Signal amplification method | |
EP0625211B1 (en) | Amplification of assay reporters by nucleic acid replication | |
JP2005521410A (en) | Methods and compositions for detection and quantification of nucleic acid analysis samples | |
US20090208932A1 (en) | Methods Of Detecting An Analyte In A Sample | |
US20040018495A1 (en) | Microparticle based signal amplification for the detection of analytes | |
EP0892856A1 (en) | A method for the amplification and detection of a nucleic acid fragment of interest | |
WO1994026932A1 (en) | Nucleic acid tagged immunoassay | |
JPH08205897A (en) | Method for testing specific bond and reagent for testing used in the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2216466 Country of ref document: CA Kind code of ref document: A Ref document number: 2216466 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970706978 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/007635 Country of ref document: MX Ref document number: 1996920100 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1996 531046 Country of ref document: JP Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1996920100 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970706978 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996920100 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019970706978 Country of ref document: KR |